• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Madrigal Pharmaceuticals Inc (NQ: MDGL )

    337.61 +6.29 (+1.90%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 773,478
    Open 331.00
    Bid (Size) 325.25 (34)
    Ask (Size) 337.00 (1)
    Prev. Close 331.32
    Today's Range 316.67 - 337.63
    52wk Range 133.99 - 337.63
    Shares Outstanding 17,103,395
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Apple Satellite Connectivity Provider Globalstar And Timberland Parent V.F Corp Are Among Top 7 Mid Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio?
    Top mid-cap stock performers: MDGL (+51.70%), PRCT (+34.20%), GSAT (+33.98%), WGS (+31.17%), NXT (+25.91%), VFC (+25.82%), OMCL (+23.22%). 
    Via Benzinga
    Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
    Madrigal sells an approved MASH treatment that blasted third-quarter sales views out of the water. 
    Via Investor's Business Daily

    Performance

    YTD
    +48.82%
    +48.82%
    1 Month
    +57.15%
    +57.15%
    3 Month
    +26.65%
    +26.65%
    6 Month
    +54.90%
    +54.90%
    1 Year
    +129.09%
    +129.09%

    More News

    Read More
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Earnings Preview For Madrigal Pharmaceuticals
    Via Benzinga
    Is Madrigal Pharmaceuticals Stock a Buy?
    Via The Motley Fool
    Is Madrigal Pharmaceuticals Stock a Buy?
    Via The Motley Fool
    This 1 Setback for Novo Nordisk Is Bullish for Madrigal Pharmaceuticals Stock
    Via The Motley Fool
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains'
    Via Investor's Business Daily
    Topics Earnings
    Exposures Financial
    Is It Too Late to Buy Madrigal Pharmaceuticals Stock?
    Via The Motley Fool
    7 Biotech Stocks to Keep on Your Clinical Radar
    Via InvestorPlace
    Is Madrigal Pharmaceuticals a Millionaire Maker?
    Via The Motley Fool
    Is Madrigal Pharmaceuticals Stock a Buy?
    Via The Motley Fool
    The Best Biotech Stock to Invest $1,000 in Right Now
    Via The Motley Fool
    Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender
    Via Investor's Business Daily
    Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word.
    Via The Motley Fool
    Where Will Madrigal Pharmaceuticals Be in 3 Years?
    Via The Motley Fool
    Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade
    Via Investor's Business Daily
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Better Biotech Stock: Viking Therapeutics vs. Madrigal Pharmaceuticals
    Via The Motley Fool
    What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
    Via Benzinga
    Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH
    Via Investor's Business Daily
    DouYu International Posts Q1 Results, Joins Annexon, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
    Via Benzinga
    Viking Therapeutics Stock Crumbles Despite Potential 'Best-In-Class' Liver Disease Drug
    Via Investor's Business Daily
    The Week Ahead: What's Next
    Via Talk Markets
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.